Tuesday, July 1, 2025 7/1/2025

Clinical characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell Carcinoma

Award Number: R01CA258442
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/15/2021
PERIOD OF PERFORMANCE END DATE: 11/30/2026

Group Awards By:

View Award Description

Clinical characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell Carcinoma - Project Summary While there are many treatment options for patients with metastatic RCC, it is still a deadly disease with considerable mortality. RCC can be much more effectively treated if it is detected early when it is amenable to surgery. To date there is no biomarker for RCC. Additionally, A specific and sensitive circulating biomarker could not only help detect this cancer earlier but could also aid in the diagnosis and monitoring of disease. This proposal seeks to test the utility of circulating kidney injury molecule-1/ T cell immunoglobulin mucin domain-1 (KIM-1/ TIM-1) as a blood test that can be used to follow patients with small renal masses and with the goal of safely avoiding or delaying surgery. We will also measure KIM1 in patients with resected RCC with the goal of identifying a high-risk patient population most likely to benefit from adjuvant therapy after nephrectomy for localized disease. This proposal will also test KIM-1 as a blood test that can help follow response to therapy for metastatic disease. To prepare for submission our team has spent considerable time and effort in identifying readily available patient samples to answer our questions. In this proposal we are poised and have samples available to address all of these questions. We hope that in the future, prospective trials will test KIM-1 in these settings but at this time, rigorous testing in these retrospective cohorts will provide the groundwork for these future studies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $382,146 )
2025	2025	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	4	12/12/2024	NON-COMPETING CONTINUATION	$382,146
														Subtotal = $382,146

Issue Date FY: 2024 ( Subtotal = $374,169 )
2024	2024	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	3	12/18/2023	NON-COMPETING CONTINUATION	$352,940
2024	2024	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Detection and Diagnosis Research	001	3	4/17/2024	NON-COMPETING CONTINUATION	$21,229
														Subtotal = $374,169

Issue Date FY: 2023 ( Subtotal = $423,811 )
2023	2023	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	2	11/22/2022	NON-COMPETING CONTINUATION	$389,217
2023	2023	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Detection and Diagnosis Research	001	2	3/22/2023	NON-COMPETING CONTINUATION	$34,594
														Subtotal = $423,811

Issue Date FY: 2022 ( Subtotal = $454,247 )
2022	2022	BETH ISRAEL DEACONESS MEDICAL CENTER, INC	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	1	12/15/2021	NEW	$454,247
														Subtotal = $454,247

Grand Total All Awards = $1,634,373

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Clinical characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell Carcinoma

Award Number: R01CA258442

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/15/2021

PERIOD OF PERFORMANCE END DATE: 11/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer